<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138039">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02127281</url>
  </required_header>
  <id_info>
    <org_study_id>CCF 14-273</org_study_id>
    <nct_id>NCT02127281</nct_id>
  </id_info>
  <brief_title>Evaluation of Wound Management With Negative Pressure Dressing Versus Standard Dressing After Revision Arthroplasty.</brief_title>
  <official_title>Randomized Controlled Trial of Wound Management With Negative Pressure Dressing Versus Standard Dressing After Knee and Hip Revision Arthroplasty.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCI USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of a negative pressure wound therapy
      (NPWT) system after revision total knee and hip arthroplasty in patients at high risk for
      infection. It is hypothesized that the use of NPWT system (i.e., Prevena) in high risk
      patients prevents wound complications and decreases reoperation rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the primary causes of un-planned readmission following lower extremity arthroplasty
      procedures is infection. Continuous wound drainage poses a serious risk for infection and is
      often initially treated with absorbent dressings and/or oral antibiotics. Comorbidities such
      as obesity, diabetes and tobacco abuse predisposes to wound complications and therefore
      infection after these procedures. NPWT has proven to be effective for postoperative drainage
      and decreases the risk for infection or further reoperation. This prospective randomized
      trial will involve 160 patients at high risk for infection undergoing revision total knee or
      hip arthroplasty; 80 patients will be randomly selected to be treated with the NPWT  system
      (Prevena) and randomly selected to be treated with the current standard of care wound
      dressing (control group). Patients will be enrolled at a single site of the Cleveland Clinic
      Health System (Main Campus).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Wound complications</measure>
    <time_frame>Within 90 days after surgery (+/-3 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complications including but not limited to drainage, blisters, cellulitis, superficial infection and deep infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Readmission and reoperation rates</measure>
    <time_frame>Within 90 days after surgery (+/- 3 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessments</measure>
    <time_frame>Within 30 days before surgery, daily during hospital stay (an expected average of 4 days), 2 weeks (+/- 3 days) after surgery, 4 weeks after surgery (+/- 3 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured from range of motion of the operated joint and time up and go (TUG) test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcomes (Functional &amp; General Health)</measure>
    <time_frame>Within 30 days before surgery, 2 weeks (+/- 3 days), 4 weeks weeks (+/- 3 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured from modified Knee Injury and Osteoarthritis Outcome Score (KOOS) or Hip Osteoarthritis Outcome Score (HOOS) and Short Form Health Survey version 2 (SF-12 v2) questionnaires.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Prosthesis-related Infections</condition>
  <condition>Wound Complications</condition>
  <condition>Joint Diseases</condition>
  <condition>Musculoskeletal Diseases</condition>
  <arm_group>
    <arm_group_label>Prevena</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>A standard of care sterile wound dressing will be placed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prevena</intervention_name>
    <description>Device will be applied at end of procedure over closed incision.</description>
    <arm_group_label>Prevena</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled revision Total Hip or Knee  Arthroplasty Procedure

          -  Presence of one of the following: body mass index (BMI) greater than 35, use of blood
             thinners other than acetylsalicylic acid (ASA) after surgery, peripheral vascular
             disease, depression, diabetes mellitus, current tobacco use, history of prior
             infection, current use of immunomodulators or steroids, current history of cancer or
             hematological malignancy, rheumatoid arthritis, renal failure or dialysis,
             malnutrition, liver disease, transplant status, or HIV.

        Exclusion Criteria:

          -  Patient lives &gt;100 miles from hospital

          -  Patient is &lt; 18 years old

          -  Silver allergy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Higuera-Rueda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>440195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alison K Klika, MS</last_name>
      <phone>216-444-4954</phone>
      <email>klikaa@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Marcelo BP Siqueira, MD</last_name>
      <phone>216-444-5022</phone>
      <email>bogliom@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Higuera-Rueda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wael K Barsoum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Viktor E Krebs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Molloy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Trevor G Murray, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Bloomfield, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hansen E, Durinka JB, Costanzo JA, Austin MS, Deirmengian GK. Negative pressure wound therapy is associated with resolution of incisional drainage in most wounds after hip arthroplasty. Clin Orthop Relat Res. 2013 Oct;471(10):3230-6. doi: 10.1007/s11999-013-2937-3.</citation>
    <PMID>23539123</PMID>
  </reference>
  <reference>
    <citation>Bozic KJ, Kurtz SM, Lau E, Ong K, Chiu V, Vail TP, Rubash HE, Berry DJ. The epidemiology of revision total knee arthroplasty in the United States. Clin Orthop Relat Res. 2010 Jan;468(1):45-51. Epub 2009 Jun 25.</citation>
    <PMID>19554385</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>April 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Carlos Higuera-Rueda</investigator_full_name>
    <investigator_title>Staff, Adult Reconstruction</investigator_title>
  </responsible_party>
  <keyword>Revision total knee arthroplasty</keyword>
  <keyword>Revision total hip arthroplasty</keyword>
  <keyword>Negative pressure wound therapy system (NPWT)</keyword>
  <keyword>Drainage</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Musculoskeletal Diseases</mesh_term>
    <mesh_term>Prosthesis-Related Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
